MARLBOROUGH, Mass.-- Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has withdrawn its previously announced public offering of 10,000,000 shares of common stock under its shelf registration statement given current market conditions.